Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

NCT02089126 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Gemigliptin/Glimepiride combination

Sponsor

LG Life Sciences